Hemostasis and Tissue Sealing Agents - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The hemostasis & tissue sealing agents market size is expected to grow from USD 9.88 billion in 2025 to USD 10.68 billion in 2026 and is forecast to reach USD 15.74 billion by 2031 at 8.07% CAGR over 2026-2031. This report is Segmented by Product Type (Topical Hemostats [Mechanical Hemostats, and More], Tissue Sealing Agents, and Adhesives), Material (Gelatin Based, Collagen-Based, and More), Application (General Surgery, Minimally Invasive Surgery, and More), End-User (Hospitals, and More), and Geography (North America, Europe and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Hemostasis And Tissue Sealing Agents Market Trends and Insights

Increasing Prevalence of Chronic Blood Disorders

Hemophilia A affects 17.1 per 100,000 males worldwide, and the total diagnosed hemophilia population surpassed 273,000 in 2024, leaving hundreds of thousands more undiagnosed. Annual direct care costs for a single patient can rise beyond USD 869,940, motivating hospitals to adopt advanced sealants that shorten procedures and reduce blood loss. Von Willebrand disease adds further demand diversity, as peri-operative bleeding risks differ across demographic groups. Gene-therapy protocols now reaching commercialization in hemophilia B often require catheter-based liver infusion, increasing surgical complexity and the need for precision bleeding control. Collectively, these patient pools ensure long-term volume growth for the hemostasis & tissue sealing agents market.

Rising Number of Surgical Procedures & Trauma Cases

Penetrating abdominal trauma represents 24% of trauma admissions, making rapid hemostasis a determinant of survival in both military and civilian settings. Evidence shows that pre-hospital tranexamic acid can cut 24-hour mortality by 19.6% in trauma victims, supporting broader pre-operative use of topical or flowable sealants that augment systemic therapies. Beyond trauma, the global surgical backlog created during the pandemic continues to unwind, lifting elective orthopedic and cardiovascular procedure counts and bolstering steady demand for the hemostasis & tissue sealing agents market.

High Product Cost

Premium sealants can exceed USD 350 per unit, a burden for facilities where reimbursements trend flat while labor and supply costs climb. Hospitals increasingly request health-economic dossiers that link higher acquisition prices to reductions in transfusions or readmissions. Emerging biosimilars and synthetic alternatives are beginning to narrow price gaps, yet formulary committees in lower-income regions still opt for oxidized cellulose gauze, tempering adoption in part of the hemostasis & tissue sealing agents market.

Other drivers and restraints analyzed in the detailed report include:

• Broader Applicability Across Multiple Specialties
• Growing Adoption of Minimally Invasive Surgery
• Stringent Regulatory & Approval Pathways

Segment Analysis

Topical Hemostats captured 42.78% of the hemostasis & tissue sealing agents market share in 2025 thanks to decades of surgeon familiarity and broad procedural coverage. They remain staples in orthopedics and general surgery, where quick mechanical tamponade is often sufficient. Yet growth is slower because the segment’s formulations are mature and face commoditization. Tissue Sealing Agents, by contrast, are forecast to advance at a 9.98% CAGR as they introduce dual-function capabilities that both halt bleeding and bond tissue planes, shortening suturing time. Flowable fibrin sealants deliver 92.4% hemostasis within 4 minutes, while synthetic polyethylene glycol glues resist washout in high-flow fields, extending indications to cardiovascular repairs. Room-temperature storage in products such as Hemopatch removes logistical barriers, widening rural and military adoption.

Mechanical sponges still dominate high-volume trauma kits, yet bio-engineered sealants now integrate antibacterial agents to lower infection risk, lifting their value proposition. The hemostasis & tissue sealing agents market benefits as procurement teams bundle these sealants with staplers and energy devices, creating cross-selling momentum. Looking forward, plant-based gels that polymerize on contact with blood are expected to win shelf space in emergency response bags because they combine rapid action with easy disposal. These dynamics underpin the sustained double-digit expansion of tissue sealing agents within the broader hemostasis & tissue sealing agents market.

Collagen formulations commanded 36.10% of 2025 revenue on the strength of long-term safety records and natural resorption profiles. Surgeons appreciate their pliability, which allows patching of irregular surfaces. Gelatin foams provide lower-cost alternatives for routine cases, but they swell several times their volume, limiting use in constrained anatomy. Oxidized regenerated cellulose (ORC) fills niche requirements where acidic pH helps with bacteriostasis.

Polysaccharide-based platforms now record the fastest 12.41% CAGR, a trend driven by breakthroughs such as aldehyde-modified riclin sponges that absorb 59.4 g/g of blood and seal porcine wounds in 30 seconds. Chitosan-derived adhesive films under evaluation for meniscus repair illustrate material versatility across orthopedic sports medicine. Beyond performance, these bio-sourced inputs sidestep plasma-supply volatility and align with hospital sustainability targets. As a result, polysaccharides are steadily expanding their foothold in the hemostasis & tissue sealing agents market, particularly within Asia-Pacific systems that prefer plant-origin consumables for cultural and regulatory reasons.

Complete Report Scope:

• By Product Type
  • Topical Hemostats
    • Mechanical Hemostats
    • Active Hemostats
    • Flowable Hemostats
  • Tissue Sealing Agents
    • Fibrin Sealants
    • Synthetic Sealants
  • Adhesives
    • Cyanoacrylate
    • Albumin & Glutaraldehyde
• By Material
  • Gelatin-based
  • Collagen-based
  • ORC-based
  • Polysaccharide-based
• By Application
  • General Surgery
  • Minimally-Invasive Surgery
  • Trauma
  • Hemophilia
  • Other Applications
• By End-User
  • Hospitals
  • Ambulatory Surgical Centers
  • Other End-Users
• Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America captured 39.55% of 2025 revenue for the hemostasis & tissue sealing agents market. The region benefits from high procedural intensity, robust reimbursement, and a proactive regulatory environment. FDA clearance of the first acellular tissue-engineered vessel for extremity trauma underscores the agency’s support for innovation, giving local developers a home-field advantage. Supply chain resilience remains top of mind after plasma shortages highlighted reliance on imported raw materials, prompting investments in domestic facilities for fibrinogen purification.

Asia-Pacific delivers the highest 9.38% CAGR, driven by expanding hospital infrastructure and medical tourism. India’s hospital market is forecast to reach USD 193 billion by 2032, more than doubling 2024 levels, and this infrastructure build-out directly boosts consumable requirements. In China, procurement reforms are pressuring price points, so vendors emphasize evidence of reduced transfusion rates and shorter stays to justify premium sealants. Japan, South Korea, and Singapore continue to pioneer robotic and hybrid OR installations that naturally rely on advanced bleeding management tools, feeding further growth in the hemostasis & tissue sealing agents market.

Europe sustains a substantial but slower-growing share amid MDR compliance costs and raw-material constraints. The continent’s push for 2 million new plasma donors aims to lower dependence on US supply. Sustainability mandates also spur demand for biodegradable patches, giving European polymer research centers an innovation edge. Meanwhile, reimbursement systems that reward outcomes should eventually favor higher-performance sealants able to document reductions in re-operation rates, supporting a steady contribution to the global hemostasis & tissue sealing agents market.

List of Companies Covered in this Report:

• Baxter
• B. Braun Holding GmbH & Co. KG
• Beckton Dickinson
• Integra LifeSciences Corp.
• Johnson & Johnson
• Medtronic
• Pfizer
• Smiths Group
• Terumo Corp.
• CSL Behring
• Grifols
• Artivion (CryoLife)
• Teleflex
• Adhezion Biomedical
• Hemostasis
• Arch Therapeutics
• Marine Polymer Technologies
• Betatech Medical
• Aegis LifeSciences

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support